GlassScriptPhysician profile
Josephine V Jasper
NPI 1962571752
$1,953.49
in general payments reported to CMS, 2019-2025
25 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $208 · 2021: $316 · 2022: $445 · 2023: $57.15 · 2024: $174 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $500.16 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $278.57 | 2020-2025 | Freestyle Libre 3 |
| Bigfoot Biomedical INC | $215.75 | 2022 | |
| Dexcom, INC. | $157.04 | 2019-2025 | Dexcom G6 Transmitter |
| Valeritas, INC. | $152.97 | 2019 | |
| Mannkind Corporation | $150.43 | 2019-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.35 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $120.62 | 2021-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $83.12 | 2024-2025 | Korlym |
| Tandem Diabetes Care, INC. | $75.10 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $58.19 | 2020-2022 | |
| Insulet Corporation | $57.28 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $55.86 | 2023-2024 | Jardiance |
| Abbvie INC. | $54.68 | 2020-2024 | |
| Sequel Med Tech, LLC | $53.44 | 2025 | Twiist |
| Arthrex, INC. | $45.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $39.35 | 2020-2023 | Tirosint, Licart |
| Novo Nordisk INC | $36.68 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $33.16 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $29.08 | 2019 | |
| Radius Health, INC. | $29.02 | 2019-2024 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $21.75 | 2020 | |
| Amneal Pharmaceuticals LLC | $21.50 | 2024 | Unithroid |
| Nestle Healthcare Nutrition INC. | $17.61 | 2021 | |
| Kvk-Tech, INC. | $15.00 | 2019 | |
| Allergan, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josephine Jasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.